Ayala’s IPO Raises $55M to Test Two Former Bristol Myers Cancer Drugs

Ayala Pharmaceuticals has two clinical-stage cancer drugs licensed from Bristol Myers Squibb. Now it has $55 million to take those drugs further than the pharmaceutical giant did.

On Thursday evening, Ayala priced its IPO, which consisted of 3.7 million shares sold for $15 each.